Omics Biomarkers for Monitoring Tuberculosis Treatment: A Mini-Review of Recent Insights and Future Approaches

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2022 Jun 6

PMID 35664683

Authors

Dian Ayu Eka Pitaloka

Mas Rizky Anggun A A Syamsunarno

Rizky Abdulah

Lidya Chaidir

Affiliations

Soon will be listed here.

Abstract

Poor sensitivity of sputum conversion for monitoring tuberculosis (TB) treatment that makes identification of a non-sputum-based biomarker is urgently needed. Monitoring biomarkers in TB treatment is used to decide whether critical thresholds have been reached and helps clinicians to conclude the therapeutic success. In this mini review, we highlight recent studies on omics-related contributes to identifying of a novel biomarker as surrogate markers for the cure and predicting future reactivation risk following TB treatment. We catalogue the studies published to seek the progress made in transcriptomics, proteomics, and metabolomics in pulmonary TB. We also discuss how integrative multi-omics data will provide further understanding and effective TB treatment, such as revealing the interrelationships at multiple molecular levels, facilitating the identification of biologically interconnected processes, and accelerating precision medicine in TB treatment. However, proper validation in prospective longitudinal studies with long-term follow-up and outcome assessment must be conducted before the biomarkers are utilized in clinical practice.

Citing Articles

C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay.

Russomando G, Sanabria D, Diaz Acosta C, Rojas L, Franco L, Arenas R Front Immunol. 2024; 15:1308015.

PMID: 38545118 PMC: 10967656. DOI: 10.3389/fimmu.2024.1308015.

New Insights into Biomarkers for Evaluating Therapy Efficacy in Pulmonary Tuberculosis: A Narrative Review.

Zhang F, Zhang F, Dong Y, Li L, Pang Y Infect Dis Ther. 2023; 12(12):2665-2689.

PMID: 37938418 PMC: 10746651. DOI: 10.1007/s40121-023-00887-x.

Research progress of single-cell sequencing in tuberculosis.

Pan J, Chang Z, Zhang X, Dong Q, Zhao H, Shi J Front Immunol. 2023; 14:1276194.

PMID: 37901241 PMC: 10611525. DOI: 10.3389/fimmu.2023.1276194.

Development and validation of assessment instrument for the perception and attitude toward tuberculosis among the general population in Indonesia: a Rasch analysis of psychometric properties.

Pitaloka D, Kusuma I, Pratiwi H, Pradipta I Front Public Health. 2023; 11:1143120.

PMID: 37841718 PMC: 10568030. DOI: 10.3389/fpubh.2023.1143120.

Trends and challenges of multi-drug resistance in childhood tuberculosis.

Zhuang Z, Sun L, Song X, Zhu H, Li L, Zhou X Front Cell Infect Microbiol. 2023; 13:1183590.

PMID: 37333849 PMC: 10275406. DOI: 10.3389/fcimb.2023.1183590.

References

Ozdemir V, Dove E, Gursoy U, Sardas S, Yildirim A, Yilmaz S . Personalized medicine beyond genomics: alternative futures in big data-proteomics, environtome and the social proteome. J Neural Transm (Vienna). 2015; 124(1):25-32. DOI: 10.1007/s00702-015-1489-y. View

West L, Vidwans S, Campbell N, Shrager J, Simon G, Bueno R . A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906. PMC: 3283716. DOI: 10.1371/journal.pone.0031906. View

Nezenega Z, Perimal-Lewis L, Maeder A . Factors Influencing Patient Adherence to Tuberculosis Treatment in Ethiopia: A Literature Review. Int J Environ Res Public Health. 2020; 17(15). PMC: 7432798. DOI: 10.3390/ijerph17155626. View

Jiang T, Shi L, Chen J, Wei L, Li M, Hu Y . Screening and identification of potential protein biomarkers for evaluating the efficacy of intensive therapy in pulmonary tuberculosis. Biochem Biophys Res Commun. 2018; 503(4):2263-2270. DOI: 10.1016/j.bbrc.2018.06.147. View

Namuganga A, Chegou N, Mayanja-Kizza H . Past and Present Approaches to Diagnosis of Active Pulmonary Tuberculosis. Front Med (Lausanne). 2021; 8:709793. PMC: 8495065. DOI: 10.3389/fmed.2021.709793. View

Higdon R, Earl R, Stanberry L, Hudac C, Montague E, Stewart E . The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders. OMICS. 2015; 19(4):197-208. PMC: 4389910. DOI: 10.1089/omi.2015.0020. View

Vrieling F, Alisjahbana B, Sahiratmadja E, van Crevel R, Harms A, Hankemeier T . Plasma metabolomics in tuberculosis patients with and without concurrent type 2 diabetes at diagnosis and during antibiotic treatment. Sci Rep. 2019; 9(1):18669. PMC: 6904442. DOI: 10.1038/s41598-019-54983-5. View

Cliff J, Cho J, Lee J, Ronacher K, King E, van Helden P . Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment. J Infect Dis. 2015; 213(3):485-95. PMC: 4704670. DOI: 10.1093/infdis/jiv447. View

Wang C, Yang S, Liu C, Jiang T, Chen Z, Tu H . Screening and identification of four serum miRNAs as novel potential biomarkers for cured pulmonary tuberculosis. Tuberculosis (Edinb). 2018; 108:26-34. DOI: 10.1016/j.tube.2017.08.010. View

10.

Misra B, Langefeld C, Olivier M, Cox L . Integrated Omics: Tools, Advances, and Future Approaches. J Mol Endocrinol. 2018; . DOI: 10.1530/JME-18-0055. View

11.

Dutta N, Tornheim J, Fukutani K, Paradkar M, Tiburcio R, Kinikar A . Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children. Sci Rep. 2020; 10(1):19527. PMC: 7658223. DOI: 10.1038/s41598-020-75513-8. View

12.

Montaner J, Ramiro L, Simats A, Tiedt S, Makris K, Jickling G . Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol. 2020; 16(5):247-264. DOI: 10.1038/s41582-020-0350-6. View

13.

Warsinske H, Rao A, Moreira F, Santos P, Liu A, Scott M . Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response. JAMA Netw Open. 2019; 1(6):e183779. PMC: 6324428. DOI: 10.1001/jamanetworkopen.2018.3779. View

14.

Padayatchi N, Daftary A, Naidu N, Naidoo K, Pai M . Tuberculosis: treatment failure, or failure to treat? Lessons from India and South Africa. BMJ Glob Health. 2019; 4(1):e001097. PMC: 6357918. DOI: 10.1136/bmjgh-2018-001097. View

15.

de Tayrac M, LE S, Aubry M, Mosser J, Husson F . Simultaneous analysis of distinct Omics data sets with integration of biological knowledge: Multiple Factor Analysis approach. BMC Genomics. 2009; 10:32. PMC: 2636827. DOI: 10.1186/1471-2164-10-32. View

16.

Magombedze G, Pasipanodya J, Gumbo T . Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse. Commun Biol. 2021; 4(1):664. PMC: 8172544. DOI: 10.1038/s42003-021-02184-0. View

17.

Rockwood N, du Bruyn E, Morris T, Wilkinson R . Assessment of treatment response in tuberculosis. Expert Rev Respir Med. 2016; 10(6):643-54. PMC: 4949330. DOI: 10.1586/17476348.2016.1166960. View

18.

Wu C, Zhou F, Ren J, Li X, Jiang Y, Ma S . A Selective Review of Multi-Level Omics Data Integration Using Variable Selection. High Throughput. 2019; 8(1). PMC: 6473252. DOI: 10.3390/ht8010004. View

19.

Yi W, Han Y, Wei L, Shi L, Huang H, Jiang T . l-Histidine, arachidonic acid, biliverdin, and l-cysteine-glutathione disulfide as potential biomarkers for cured pulmonary tuberculosis. Biomed Pharmacother. 2019; 116:108980. DOI: 10.1016/j.biopha.2019.108980. View

20.

Thompson E, Du Y, Malherbe S, Shankar S, Braun J, Valvo J . Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis (Edinb). 2017; 107:48-58. PMC: 5658513. DOI: 10.1016/j.tube.2017.08.004. View